-
-
Overview
-
Please contact us at for specific academic pricing.
Background
CB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft.
-
- Properties
-
Overview